var data={"title":"Deferasirox: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Deferasirox: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/146801?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=deferasirox-drug-information\" class=\"drug drug_general\">see &quot;Deferasirox: Drug information&quot;</a> and <a href=\"topic.htm?path=deferasirox-patient-drug-information\" class=\"drug drug_patient\">see &quot;Deferasirox: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9935104\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal failure:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders. Measure serum creatinine and determine CrCl in duplicate prior to initiation of therapy and monitor renal function at least monthly thereafter. For patients with baseline renal impairment or at increased risk of acute renal failure, monitor creatinine weekly for the first month, and then at least monthly. Consider dose reduction, interruption, or discontinuation based on increases in serum creatinine.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatic failure:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox can cause hepatic injury, including hepatic failure and death. Measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly thereafter. Avoid use of deferasirox in patients with severe (Child-Pugh class C) hepatic impairment and reduce the dose in patients with moderate (Child-Pugh class B) hepatic impairment.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gastrointestinal hemorrhage:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox can cause GI hemorrhages, which may be fatal, especially in elderly patients who have advanced hematologic malignancies and/or low platelet counts. Monitor patients and discontinue deferasirox for suspected GI ulceration or hemorrhage.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987209\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Exjade;</li>\n      <li>Jadenu;</li>\n      <li>Jadenu Sprinkle</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4432114\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Exjade;</li>\n      <li>Jadenu</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738373\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Chelating Agent, Oral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738403\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=deferasirox-drug-information\" class=\"drug drug_general\">see &quot;Deferasirox: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note: </b>Deferasirox is available in two formulations (Exjade: Tablets for oral suspension, Jadenu: Tablets) that are <b>not</b> bioequivalent on a mg:mg basis due to bioavailability differences. Calculate dose to the nearest whole tablet size.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion from Exjade to Jadenu:</b> The dose for Jadenu should be ~30% lower than Exjade (doses rounded to the nearest whole tablet).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blood transfusion; chronic iron overload:</b> Children &ge;2 years and Adolescents: Oral: <b>Note:</b> Treatment should only be initiated with evidence of chronic iron overload [ie, transfusion of &ge;100 mL/kg of packed RBCs (eg, &ge;20 units for a 40 kg individual) and serum ferritin consistently &gt;1000 mcg/L].</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Exjade (oral tablet for suspension):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 20 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: Adjust dose every 3 to 6 months based on serum ferritin levels; increase dose by 5 or 10 mg/kg/day increments; usual range: 20 to 30 mg/kg/day; for serum ferritin levels persistently &gt;2,500 mcg/L without evidence of a decreasing trend, may consider a dose of 40 mg/kg/day; doses &gt;40 mg/kg/day are not recommended. If serum ferritin is &lt;500 mcg/L, interrupt therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Jadenu (oral tablet):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 14 mg/kg once daily, calculate dose to the nearest whole tablet</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: Adjust dose every 3 to 6 months based on serum ferritin trends; adjust by 3.5 or 7 mg/kg/day; titrate to individual response and treatment goals. In patients not adequately controlled at a dose of 21 mg/kg/day (eg, serum ferritin levels persistently &gt;2,500 mcg/L and not decreasing over time), then higher doses up to 28 mg/kg/day may be considered; doses &gt;28 mg/kg/day are not recommended). If serum ferritin is &lt;500 mcg/L, interrupt therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nontransfusion-dependent chronic iron overload; thalassemia syndromes:</b> Children &ge;10 years and Adolescents: Oral: <b>Note:</b> Treatment should only be initiated with evidence of chronic iron overload (hepatic iron concentration &ge;5 mg Fe/g dry weight and serum ferritin &gt;300 mcg/L).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Exjade (oral tablet for suspension):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 10 mg/kg once daily; after 4 weeks; if baseline hepatic iron concentration was &gt;15 mg Fe/g dry weight, may increase to 20 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: Dependent upon serum ferritin measurements (monthly) and hepatic iron concentrations (every 6 months)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If serum ferritin is &lt;300 mcg/L: Interrupt therapy and obtain hepatic iron concentration</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If hepatic iron concentration:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;3 mg Fe/g dry weight: Interrupt therapy; resume treatment when hepatic iron concentration is &gt;5 mg Fe/g dry weight</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">3 to 7 mg Fe/g dry weight: Continue treatment at a dose &le;10 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;7 mg Fe/g dry weight: Consider dose increase to 20 mg/kg/day; repeat measurement and if remains &gt;7 mg Fe/g dry weight, continue current dose; if repeat measurement is 3 to 7 mg Fe/g dry weight, then decrease dose to 10 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Jadenu (oral tablet):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 7 mg/kg once daily; after 4 weeks, if hepatic iron concentration was &gt;15 mg Fe/g dry weight, may increase to 14 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: Dependent upon serum ferritin measurements (monthly) and hepatic iron concentrations (every 6 months)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If serum ferritin is &lt;300 mcg/L: Interrupt therapy and obtain hepatic iron concentration</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If hepatic iron concentration:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;3 mg Fe/g dry weight: Interrupt therapy; resume treatment when hepatic iron concentration is &gt;5 mg Fe/g dry weight</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">3 to 7 mg Fe/g dry weight: Continue treatment at a dose &le;7 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;7 mg Fe/g dry weight: Consider dose increase to 14 mg/kg/day; repeat measurement and if remains &gt;7 mg Fe/g dry weight, continue current dose; if repeat measurement is 3 to 7 mg Fe/g dry weight, then decrease dose to &le;7 mg/kg/day. Maximum daily dose: 14 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion from Exjade to Jadenu:</b> The dose for Jadenu should be ~30% lower (rounded to the nearest whole tablet).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic iron overload due to transfusions:</b> Oral: <b>Note:</b> Treatment should only be initiated with evidence of chronic iron overload (ie, transfusion of &ge;100 mL/kg of packed red blood cells [eg, &ge;20 units for a 40 kg individual] and serum ferritin consistently &gt;1,000 mcg/L).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Exjade (oral tablet for suspension):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 20 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: <b>Note</b>: Consider interrupting therapy for serum ferritin &lt;500 mcg/L (risk of toxicity may be increased). Adjust dose every 3 to 6 months based on serum ferritin trends; adjust by 5 or 10 mg/kg/day; titrate to individual response and treatment goals. In patients not adequately controlled with 30 mg/kg/day, doses up to 40 mg/kg/day may be considered for serum ferritin levels persistently &gt;2,500 mcg/L and not decreasing over time (doses above 40 mg/kg/day are not recommended).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Jadenu (oral tablet):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 14 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: <b>Note:</b> Consider interrupting therapy for serum ferritin &lt;500 mcg/L (risk of toxicity may be increased). Adjust dose every 3 to 6 months based on serum ferritin trends; adjust by 3.5 or 7 mg/kg/day; titrate to individual response and treatment goals. In patients not adequately controlled with 21 mg/kg/day, doses up to 28 mg/kg/day may be considered for serum ferritin levels persistently &gt;2,500 mcg/L and not decreasing over time (doses above 28 mg/kg/day are not recommended).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic iron overload in nontransfusion-dependent thalassemia syndromes:</b> Oral: <b>Note:</b> Treatment should only be initiated with evidence of chronic iron overload (hepatic iron concentration &ge;5 mg Fe/g dry weight and serum ferritin &gt;300 mcg/L).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Exjade (oral tablet for suspension):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 10 mg/kg once daily. Consider increasing to 20 mg/kg once daily after 4 weeks if baseline hepatic iron concentration is &gt;15 mg Fe/g dry weight</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: Monitor serum ferritin monthly; if serum ferritin is &lt;300 mcg/L, interrupt therapy and obtain hepatic iron concentration. Monitor hepatic iron concentration every 6 months; interrupt therapy if hepatic iron concentration &lt;3 mg Fe/g dry weight. After 6 months of therapy, consider dose adjustment to a maximum of 20 mg/kg/day if hepatic iron concentration &gt;7 mg Fe/g dry weight. Reduce dose to &le;10 mg/kg when hepatic iron concentration is 3 to 7 mg Fe/g dry weight. Do not exceed 20 mg/kg/day. After interruption, resume treatment when hepatic iron concentration &gt;5 mg Fe/g dry weight.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Jadenu (oral tablet):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 7 mg/kg once daily. Consider increasing to 14 mg/kg once daily after 4 weeks if baseline hepatic iron concentration is &gt;15 mg Fe/g dry weight.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: Monitor serum ferritin monthly; if serum ferritin is &lt;300 mcg/L, interrupt therapy and obtain hepatic iron concentration. Monitor hepatic iron concentration every 6 months; interrupt therapy if hepatic iron concentration &lt;3 mg Fe/g dry weight. After 6 months of therapy, consider dose adjustment to a maximum of 14 mg/kg/day if hepatic iron concentration &gt;7 mg Fe/g dry weight. Reduce dose to &le;7 mg/kg when hepatic iron concentration is 3 to7 mg Fe/g dry weight. Do not exceed 14 mg/kg/day. After interruption, resume treatment when hepatic iron concentration &gt;5 mg Fe/g dry weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment with concomitant bile acid sequestrants (eg, cholestyramine, colesevelam, colestipol) or potent UGT inducers (eg, rifampin, phenytoin, phenobarbital, ritonavir):</b> Children &ge;2 years and Adolescents: Avoid concomitant use; if coadministration necessary, consider increasing the initial deferasirox dose by 50%; monitor serum ferritin and clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Baseline:</i> Children &ge;2 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 60 mL/minute: Reduce initial dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;40 mL/minute or serum creatinine &gt;2 x age-appropriate ULN: Use is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>During therapy:</i> Adjustment dependent upon indication for use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Transfusional iron overload: </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;2 years and Adolescents &lt;16 years: For increase in serum creatinine &ge;33% above the average baseline level and above the age-appropriate ULN: Reduce daily dose <b>by</b> 10 mg/kg/day (for Exjade) or 7 mg/kg (for Jadenu)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;16 years and Adults: If increase in serum creatinine &ge;33% above the average baseline: Repeat serum creatinine measurement in 1 week; if still elevated by &ge;33%: Reduce daily dose <b>by</b> 10 mg/kg/day (for Exjade) or 7 mg/kg (for Jadenu)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">All patients: If serum creatinine &gt;2 times age-appropriate ULN or CrCl &lt;40 mL/minute: Discontinue therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Nontransfusion-dependent thalassemia syndromes: </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;10 years and Adolescents &lt;16 years: For increase in serum creatinine &ge;33% above the average baseline level and above the age-appropriate ULN: Reduce daily dose <b>by</b> 5 mg/kg/day (for Exjade) or 3.5 mg/kg (for Jadenu)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;16 years and Adults: If increase in serum creatinine &ge;33% above the average baseline; repeat serum creatinine measurement in 1 week; if still elevated <b>by</b> &ge;33%:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Exjade: Interrupt therapy if the dose is 5 mg/kg; reduce dose <b>by</b> 50% if the dose is 10 or 20 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Jadenu: Interrupt therapy if the dose is 3.5 mg/kg; reduce dose <b>by</b> 50% if the dose is 7 or 14 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">All patients: If serum creatinine &gt;2 times age-appropriate ULN or CrCl &lt;40 mL/minute: Discontinue therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children &ge;2 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Baseline:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild impairment (Child-Pugh class A): No adjustment necessary; monitor closely for efficacy and for adverse reactions requiring dosage reduction</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate impairment (Child-Pugh class B): Reduce dose <b>by</b> 50%; monitor closely for efficacy and for adverse reactions requiring dosage reduction</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment (Child-Pugh class C): Avoid use</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i> During therapy:</i> Severe or persistent increases in transaminases/bilirubin: Reduce dose or temporarily interrupt treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity: </b>Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bone marrow suppression: Interrupt treatment; may reinitiate once cause of cytopenia has been determined; contraindicated if platelet count &lt;50,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rash (severe): Interrupt treatment; may reintroduce at a lower dose (with future dose escalation) and short-term oral corticosteroids</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe skin reaction (Stevens-Johnson syndrome, erythema multiforme): Discontinue and evaluate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Discontinue treatment for suspected GI ulceration or hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hearing loss or visual disturbance: Consider dose reduction or treatment interruption</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987300\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jadenu Sprinkle: 90 mg (1 ea, 30 ea); 180 mg (1 ea, 30 ea); 360 mg (1 ea, 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jadenu: 90 mg, 180 mg, 360 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Soluble, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Exjade: 125 mg, 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1988061\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738404\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets (Jadenu): Administer with water or other liquids at the same time each day. Administer on an empty stomach or with a light meal (containing less than 7% fat content and ~250 calories). Do not administer simultaneously with aluminum-containing antacids or cholestyramine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets for oral suspension (Exjade):  Administer tablets by making an oral suspension; <b>do not chew or swallow whole tablets</b>. Stir to form suspension and drink entire contents. Rinse remaining residue with more fluid; drink. Administer at same time each day on an empty stomach, at least 30 minutes before food. Do not administer simultaneously with aluminum-containing antacids or cholestyramine.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987252\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738374\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of chronic iron overload due to blood transfusions (FDA approved in ages &ge;2 years and adults); treatment of chronic iron overload due to nontransfusion-dependent thalassemia syndromes with a liver iron concentration (LIC) of at least 5 mg iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin &gt;300 mcg/L (FDA approved in ages &ge;10 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4432943\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Deferasirox may be confused with deferiprone, deferoxamine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987244\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, dizziness, fatigue, headache (Phatak 2010; Vichinsky 2007), sleep disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dyschromia, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, acute pancreatitis, cholelithiasis, constipation (Vichinsky 2007), diarrhea, duodenal ulcer, gastric ulcer, gastritis, gastrointestinal hemorrhage, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum bilirubin (Vichinsky 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Viral infection (Vichinsky 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (Vichinsky 2007), back pain (Vichinsky 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Cataract, maculopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Hearing loss (including high frequency)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine, renal tubular disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (Vichinsky 2007), nasopharyngitis (Vichinsky 2007), pharyngitis (Vichinsky 2007), pharyngolaryngeal pain, respiratory tract infection (Vichinsky 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal hepatic function tests, acute renal failure, agranulocytosis, alopecia, anaphylaxis, anemia (worsening), angioedema, DRESS syndrome, drug fever, erythema multiforme, esophagitis, Fanconi syndrome, gastrointestinal perforation, glycosuria, hepatic failure, hepatic insufficiency, hepatitis, hyperactivity, hypersensitivity angiitis, hypersensitivity reaction, IgA vasculitis, increased intraocular pressure, insomnia, interstitial nephritis, neutropenia, nontuberculous mycobacterial infection, optic neuritis, purpura, renal tubular necrosis, retinopathy, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987218\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to deferasirox or any component of the formulation; CrCl &lt;40 mL/minute or serum creatinine &gt;2 times the age-appropriate ULN; poor performance status; high-risk myelodysplastic syndromes; advanced malignancies; platelet counts &lt;50,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): MDS patients with &lt;1 year life expectancy; CrCl &lt;60 mL/minute; patients with other hematological and nonhematological malignancies who are not expected to benefit from chelation therapy (due to rapid progression of their disease)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987219\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Auditory disturbances: Decreased hearing and high-frequency hearing loss have been reported (rare) with use; perform auditory testing prior to initiation and regularly (every 12 months) during use; if abnormalities develop, monitor more closely and consider dose reduction or treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Cytopenias (including agranulocytosis, neutropenia, thrombocytopenia, and worsening anemia) have been reported (some fatal); risk may be increased in patients with preexisting hematologic disorders; monitor blood counts regularly. Interrupt treatment in patients who develop cytopenias; may reinitiate once cause of cytopenia has been determined; use contraindicated if platelet count &lt;50,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: May cause skin rash (dose-related); mild to moderate rashes may resolve without treatment interruption; for severe rash, interrupt and consider restarting at a lower dose with dose escalation and oral steroids. Severe skin reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis and erythema multiforme, have also been reported; the risk of other skin reactions including drug reaction with eosinophilia and systemic symptoms (DRESS) cannot be excluded. If severe skin reactions are suspected, discontinue immediately and evaluate; do not reintroduce therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal events: <b>[US Boxed Warning]: GI hemorrhages (including fatalities) may occur; observed more frequently in elderly patients with advanced hematologic malignancies and/or low platelet counts; discontinue treatment for suspected GI hemorrhage or ulceration. </b>Nonfatal upper GI irritation, hemorrhage, and ulceration (sometimes complicated with GI perforation, including fatalities) have been reported. Use caution with concurrent medications that may increase risk of adverse GI effects (eg, NSAIDs, corticosteroids, anticoagulants, oral bisphosphonates). Monitor patients closely for signs/symptoms of GI ulceration/bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic failure: <b>[US Boxed Warning]: Hepatic injury and failure (including fatalities) may occur. Monitor transaminases and bilirubin at baseline, every 2 weeks for 1 month, then at least monthly thereafter.</b> Hepatitis and elevated transaminases have also been reported. Hepatotoxicity is more common in patients &gt;55 years and in patients with significant comorbidities (eg, cirrhosis, multiorgan failure). Reduce dose or temporarily interrupt treatment for severe or persistent increases in transaminases/bilirubin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including severe reactions (anaphylaxis and angioedema) have been reported; onset is usually within the first month of treatment. Discontinue if reaction is severe and do not reintroduce patients with previous hypersensitivity reactions due to risk of anaphylactic shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disturbances: Lens opacities, cataracts, intraocular pressure elevation, and retinal disorders have been reported (rare) with use; perform ophthalmic testing prior to initiation and regularly (every 12 months) during use; if abnormalities develop, monitor more closely and consider dose reduction or treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: <b>[US Boxed Warning]: Acute renal failure (including fatalities and cases requiring dialysis) may occur; observed more frequently in patients with comorbid conditions and patients in advanced stages of hematologic disorders. Obtain serum creatinine and calculate CrCl in duplicate prior to initiation of therapy and monitor at least monthly thereafter. For patients with baseline renal impairment or at increased risk of acute renal failure, monitor creatinine weekly during the first month then at least monthly thereafter. Consider dose reduction, interruption, or discontinuation based on increases in serum creatinine.</b> Monitor serum creatinine and/or CrCl more frequently if creatinine levels are increasing. May cause proteinuria; monitor monthly although the clinical significance of proteinuria is unknown. Renal tubular damage, including Fanconi syndrome, has also been reported, primarily in pediatric/adolescent patients with beta-thalassemia and serum ferritin levels &lt;1,500 mcg/L. Use with caution. Dosage reduction, modification or treatment discontinuation may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment:<b> [US Boxed Warning]: Avoid use in patients with severe (Child-Pugh class C) hepatic impairment; dose reduction is required in patients with moderate (Child-Pugh class B) hepatic impairment.</b> Monitor patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) impairment closely for efficacy and for adverse reactions requiring dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: In patients with baseline renal impairment, monitor creatinine weekly during the first month then at least monthly thereafter. Consider dose reduction, interruption, or discontinuation based on increases in serum creatinine. </b>Reductions in initial dose are recommended for patients with CrCl 40 to 60 mL/minute; use is contraindicated in patients with a CrCl &lt;40 mL/minute or serum creatinine &gt;2 times age-appropriate ULN.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution due to the higher incidence of toxicity (eg, hepatotoxicity) and fatal events during use; monitor elderly patients closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Some formulations may contain lactose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For transfusion-related iron overload, treatment should be initiated with evidence of chronic iron overload (ie, transfusion of &ge;100 mL/kg of packed RBCs [eg, &ge;20 units for a 40 kg individual] and serum ferritin consistently &gt;1,000 mcg/L). For non-transfusion-dependent iron overload, initiate with liver iron concentration &ge;5 mg Fe/g dry liver weight, and serum ferritin &gt;300 mcg/L. Prior to use, consider risk versus anticipated benefit with respect to individual patient's life expectancy, prognosis, and comorbidities. An improvement in survival or disease-related symptoms due to the therapy has not been established in clinical trials. Postmarketing experience indicates serious reactions, including fatalities, have occurred with deferasirox use, particularly when used in older patients with comorbidities or advanced disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Other minerals: Deferasirox has a low affinity for binding with zinc and copper, may cause variable decreases in the serum concentration of these trace minerals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Overchelation: Overchelation of iron may increase development of toxicity; monitor sodium ferritin; consider temporary interruption of treatment in transfusional iron overload when serum ferritin &lt;500 mcg/L; in non-transfusion-dependent thalassemia when serum ferritin &lt;300 mcg/L or hepatic iron concentration &lt;3 mg Fe/g dry weight.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9935524\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of UGT1A1; <b>Inhibits</b> CYP1A2 (moderate), CYP2C8 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987249\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13104&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agomelatine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Agomelatine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: May diminish the therapeutic effect of Deferasirox.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amodiaquine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Amodiaquine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Deferasirox may increase the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.<b> Exceptions: </b>Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Hydrocortisone (Ophthalmic); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Substrates (High risk with Inhibitors): Deferasirox may increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Substrates (High risk with Inhibitors): Deferasirox may increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inducers): Deferasirox may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: Use any such combination with caution and close monitoring for pirfenidone toxicity. Avoid the use of pirfenidone with moderate CYP1A2 inhibitors whenever CYP2C9, 2C19, 2C6, or 2E1 is also inhibited (either by the CYP1A2 inhibitor or by a third drug).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: Deferasirox may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selexipag: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Selexipag. CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Selexipag.  Management: If initiating selexipag in a patient on a moderate CYP2C8 inhibitor, consider a less frequent dosing regimen (ie, once daily). If initiating a moderate CYP2C8 inhibitor in a patient on selexipag, consider a selexipag dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline: Deferasirox may increase the serum concentration of Theophylline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of TiZANidine.  Management: If combined use cannot be avoided, initiate tizanidine in adults at 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13842282\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets for oral suspension: Bioavailability is increased variably when taken with food. Management: Take on an empty stomach at the same time each day at least 30 minutes before food. Maintain adequate hydration, unless instructed to restrict fluid intake.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Bioavailability decreased slightly (not clinically meaningful) after a low-fat meal and increased after a high-fat meal. Management: Take on an empty stomach or with a light meal (containing ~250 calories and &lt;7% fat content).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987215\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987216\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Information related to the use of deferasirox in pregnant women is limited (Vini 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738405\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum ferritin (baseline, then monthly), iron levels (baseline), CBC with differential, serum creatinine, and/or creatinine clearance [two baseline assessments, then at least monthly; for patients who are at increased risk of complications (eg, pre-existing renal conditions, elderly, comorbid conditions, or receiving other potentially nephrotoxic medications): Two baseline assessments, weekly for the first month then at least monthly thereafter]; urine protein (monthly), serum transaminases (ALT/AST) and bilirubin  at baseline, every 2 weeks for 1 month, then monthly; baseline and annual auditory and ophthalmic function (including slit lamp examinations and dilated fundoscopy); performance status (in patients with hematologic malignancies); signs and symptoms of GI ulcers or hemorrhage; cumulative number of RBC units received </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987256\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selectively binds iron, forming a complex that is excreted primarily through the feces.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1987259\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Adults: 14.37 &plusmn; 2.69 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~99% to serum albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via glucuronidation by UGT1A1 (primarily) and UGT1A3; minor oxidation by CYP450; undergoes enterohepatic recirculation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Tablets for oral suspension: 70%; Tablets: 36% greater than tablets for oral suspension; Granules: 52% greater than tablets for oral suspension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 8 to 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Tablets and tablets for oral suspension: ~1.5 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (84%); urine (8%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597937\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Systemic exposure has been shown to be less in pediatric patients (2 to 16 years) compared to adults; in children 2 to 6 years, exposure was reduced by ~50% compared to adults; however, results of safety and efficacy trials using the same dose were similar in pediatric and adult patients. Patients with myelodysplastic syndromes (MDS) and CrCl of 40 to 60 mL/minute had 50% higher mean deferasirox trough concentrations compared to patients with MDS and CrCl &gt;60 mL/minute.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322889\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Jadenu Sprinkle Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (1): $46.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (1): $93.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (1): $187.67</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet,Dispersible</b> (Exjade Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (30): $1,407.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $2,815.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $5,630.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Jadenu Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (30): $1,407.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $2,815.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (30): $5,630.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539963\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Asunra (LK);</li>\n      <li>Chelaton (QA);</li>\n      <li>Clearon (BD);</li>\n      <li>Eksidzhad (UA);</li>\n      <li>Exjade (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VN);</li>\n      <li>Feresirrox (BD);</li>\n      <li>Jadenu (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bacon BR, Adams PC, Kowdley KV, et al, &quot;Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases,&quot; <i>Hepatology</i>, 2011, 54(1):328-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferasirox-pediatric-drug-information/abstract-text/21452290/pubmed\" target=\"_blank\" id=\"21452290\">21452290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cappellini MD, Bejaoui M, Agaoglu L, et al, &quot;Iron Chelation With Deferasirox in Adult and Pediatric Patients With Thalassemia Major: Efficacy and Safety During 5 Years' Follow-Up,&quot; <i>Blood</i>, 2011, 118(4):884-93. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferasirox-pediatric-drug-information/abstract-text/21628399/pubmed\" target=\"_blank\" id=\"21628399\">21628399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Exjade tablet for oral suspension (defirasirox) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2013. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galanello R, Piga A, Alberti D, et al, &quot;Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients With Transfusion-Dependent Iron Overload Due to Beta-Thalassemia,&quot; <i>J Clin Pharmacol</i>, 2003,  43(6):565-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferasirox-pediatric-drug-information/abstract-text/12817519 /pubmed\" target=\"_blank\" id=\"12817519 \">12817519 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jadenu tablets (defirasirox) [prescribing information].  East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nisbet-Brown E, Oliveri NF, Giardina PJ, et al, &quot;Effectiveness and Safety of ICL670 in Iron-Loaded Patients With Thalassaemia: A Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial,&quot; <i>Lancet</i>, 2003, 361(9369):1597-602.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferasirox-pediatric-drug-information/abstract-text/12747879/pubmed\" target=\"_blank\" id=\"12747879\">12747879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raphael JL, Bernhardt MB, Mahoney DH, et al, &quot;Oral Iron Chelation and the Treatment of Iron Overload in a Pediatric Hematology Center,&quot; <i>Pediatr Blood Cancer</i>, 2009, 52(5):616-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferasirox-pediatric-drug-information/abstract-text/19148949 /pubmed\" target=\"_blank\" id=\"19148949 \">19148949 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rund D and Rachmilewitz E, &quot;Beta-Thalassemia,&quot; <i>N Engl J Med</i>, 2005, 353(11):1135-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferasirox-pediatric-drug-information/abstract-text/16162884 /pubmed\" target=\"_blank\" id=\"16162884 \">16162884 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&eacute;chaud R, Dutreix C, Balez S, et al. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. <i>Int J Clin Pharmacol Ther</i>. 2008;46(2):102-108. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferasirox-pediatric-drug-information/abstract-text/18218291/pubmed\" target=\"_blank\" id=\"18218291\">18218291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vini D, Servos P, Drosou M. Normal pregnancy in a patient with &beta;-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade&reg;). Eur J Haematol. 2011 Mar;86(3):274-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferasirox-pediatric-drug-information/abstract-text/21198860 /pubmed\" target=\"_blank\" id=\"21198860 \">21198860 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yusuf B, McPhedran P, and Brewster UC, &quot;Hypocalcemia in a Dialysis Patient Treated With Deferasirox for Iron Overload,&quot;<i> Am J Kidney Dis</i>, 2008, 52(3):587-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferasirox-pediatric-drug-information/abstract-text/18534729/pubmed\" target=\"_blank\" id=\"18534729\">18534729</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13104 Version 130.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9935104\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F1987209\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4432114\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2738373\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2738403\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F1987300\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F1988061\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2738404\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F1987252\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2738374\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F4432943\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F1987244\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F1987218\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F1987219\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9935524\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F1987249\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F13842282\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F1987215\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1987216\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2738405\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F1987256\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F1987259\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597937\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322889\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539963\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13104|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=deferasirox-drug-information\" class=\"drug drug_general\">Deferasirox: Drug information</a></li><li><a href=\"topic.htm?path=deferasirox-patient-drug-information\" class=\"drug drug_patient\">Deferasirox: Patient drug information</a></li></ul></div></div>","javascript":null}